Back to news

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer

Business Wire•18/11/2026•06:00 ET
0

Key Highlights

  • ➤HARMONi-10 launches as Summit’s sixth sponsored Phase III ivonescimab study
  • ➤Trial compares ivonescimab against durvalumab in unresectable Stage III NSCLC
  • ➤Primary endpoint is progression-free survival in the registration-enabling study
  • ➤Global HARMONi-10 site activations are expected to begin in fourth quarter 2026
  • ➤Ivonescimab received marketing authorization in China in May 2024

Expert Statements

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“HARMONi-10 is the next bold step in a clinical development program built to change what is possible for people with lung cancer”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“We are taking ivonescimab head-to-head against standard-of-care PD-L1 therapy in this global Phase III trial, in earlier stage disease, because we believe in its potential and intend to prove it.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics

“This is the rigor, ambition, and conviction we have brought to this program from day one.”

Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“Patients with unresectable Stage III non-small cell lung cancer endure an intensive course of chemoradiation, and too often their disease still progresses thereafter despite current consolidation therapy.”

Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“In this curative-intent setting, this is a gap we are determined to close.”

Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“With PD-1 and VEGF blockade in a single molecule, we believe ivonescimab has the potential to keep the disease from progressing for longer than durvalumab in this setting.”

Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“We are moving with urgency to activate sites globally and bring ivonescimab to many more people living with lung cancer.”

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer

Global Registration-Enabling Study to Evaluate Ivonescimab Versus Durvalumab as Consolidation Therapy Following Concurrent Chemoradiation

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in